Alex Z Fu1, Huei-Ting Tsai2, Reina Haque3, Marianne Ulcickas Yood4, Andrea E Cassidy-Bushrow5, Stephen K Van Den Eeden6, Nancy L Keating7, Matthew R Smith8, Yingjun Zhou2, David S Aaronson6, Arnold L Potosky2. 1. Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, D.C.. Electronic address: zf54@georgetown.edu. 2. Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, D.C. 3. Southern California Permanente Medical Group, Kaiser Permanente Research, Pasadena, California. 4. Boston University School of Public Health, Boston, Massachusetts. 5. Henry Ford Hospital, Detroit, Michigan. 6. Kaiser Permanente Northern California, Oakland, California. 7. Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. 8. Massachusetts General Hospital, Boston, Massachusetts.
Abstract
PURPOSE: Androgen deprivation therapy is often used as salvage treatment in men with rising prostate specific antigen after initial radical prostatectomy or radiotherapy for clinically localized prostate cancer. Given the lack of evidence from general practice, we examined the association of salvage androgen deprivation therapy with mortality in an observational cohort study. MATERIALS AND METHODS: From 3 managed care organizations we assembled a retrospective cohort of all 5,804 men with newly diagnosed localized prostate cancer from 1995 to 2009 who had a prostate specific antigen increase (biochemical recurrence) after primary radical prostatectomy or radiotherapy. The main outcomes were all-cause and prostate cancer specific mortality. We used Cox proportional hazards models to estimate mortality with salvage androgen deprivation therapy as a time dependent predictor. RESULTS: Overall salvage androgen deprivation therapy was not associated with all-cause or prostate cancer specific mortality in the prostatectomy cohort (HR 0.97, 95% CI 0.70-1.35 or HR 1.18, 95% CI 0.68-2.07) or in the radiotherapy cohort (HR 0.84, 95% CI 0.70-1.01 or HR 1.06, 95% CI 0.80-1.40, respectively). Among men with prostate specific antigen doubling time less than 9 months after the prostate specific antigen rise, salvage androgen deprivation therapy was statistically significantly associated with a decreased risk of all-cause and prostate cancer specific mortality in the prostatectomy cohort (HR 0.35, 95% CI 0.20-0.63 and HR 0.43, 95% CI 0.21-0.91) and in the radiotherapy cohort (HR 0.62, 95% CI 0.48-0.80 and HR 0.65, 95% CI 0.47-0.90, respectively). CONCLUSIONS: We found no association of salvage androgen deprivation therapy with all-cause or cause specific mortality in most men with biochemical recurrence after primary radical prostatectomy or radiotherapy for clinically localized prostate cancer. Men with quickly progressed disease may derive a clinical benefit from salvage androgen deprivation therapy.
PURPOSE: Androgen deprivation therapy is often used as salvage treatment in men with rising prostate specific antigen after initial radical prostatectomy or radiotherapy for clinically localized prostate cancer. Given the lack of evidence from general practice, we examined the association of salvage androgen deprivation therapy with mortality in an observational cohort study. MATERIALS AND METHODS: From 3 managed care organizations we assembled a retrospective cohort of all 5,804 men with newly diagnosed localized prostate cancer from 1995 to 2009 who had a prostate specific antigen increase (biochemical recurrence) after primary radical prostatectomy or radiotherapy. The main outcomes were all-cause and prostate cancer specific mortality. We used Cox proportional hazards models to estimate mortality with salvage androgen deprivation therapy as a time dependent predictor. RESULTS: Overall salvage androgen deprivation therapy was not associated with all-cause or prostate cancer specific mortality in the prostatectomy cohort (HR 0.97, 95% CI 0.70-1.35 or HR 1.18, 95% CI 0.68-2.07) or in the radiotherapy cohort (HR 0.84, 95% CI 0.70-1.01 or HR 1.06, 95% CI 0.80-1.40, respectively). Among men with prostate specific antigen doubling time less than 9 months after the prostate specific antigen rise, salvage androgen deprivation therapy was statistically significantly associated with a decreased risk of all-cause and prostate cancer specific mortality in the prostatectomy cohort (HR 0.35, 95% CI 0.20-0.63 and HR 0.43, 95% CI 0.21-0.91) and in the radiotherapy cohort (HR 0.62, 95% CI 0.48-0.80 and HR 0.65, 95% CI 0.47-0.90, respectively). CONCLUSIONS: We found no association of salvage androgen deprivation therapy with all-cause or cause specific mortality in most men with biochemical recurrence after primary radical prostatectomy or radiotherapy for clinically localized prostate cancer. Men with quickly progressed disease may derive a clinical benefit from salvage androgen deprivation therapy.
Authors: Arnold L Potosky; Reina Haque; Andrea E Cassidy-Bushrow; Marianne Ulcickas Yood; Miao Jiang; Huei-Ting Tsai; George Luta; Nancy L Keating; Matthew R Smith; Stephen K Van Den Eeden Journal: J Clin Oncol Date: 2014-03-17 Impact factor: 44.544
Authors: Stephen J Freedland; Elizabeth B Humphreys; Leslie A Mangold; Mario Eisenberger; Frederick J Dorey; Patrick C Walsh; Alan W Partin Journal: JAMA Date: 2005-07-27 Impact factor: 56.272
Authors: Gillian M Duchesne; Henry H Woo; Julie K Bassett; Steven J Bowe; Catherine D'Este; Mark Frydenberg; Madeleine King; Leo Ledwich; Andrew Loblaw; Shawn Malone; Jeremy Millar; Roger Milne; Rosemary G Smith; Nigel Spry; Martin Stockler; Rodney A Syme; Keen Hun Tai; Sandra Turner Journal: Lancet Oncol Date: 2016-05-04 Impact factor: 41.316
Authors: Roderick C N van den Bergh; Niels J van Casteren; Thomas van den Broeck; Eve R Fordyce; William K M Gietzmann; Fiona Stewart; Steven MacLennan; Saeed Dabestani; Joaquim Bellmunt; Michel Bolla; Erik Briers; Philip Cornford; Steven Joniau; Malcolm D Mason; Vsevolod Matveev; Henk G van der Poel; Theo H van der Kwast; Olivier Rouvière; Thomas Wiegel; Thomas B Lam; Nicolas Mottet Journal: Eur Urol Date: 2015-12-12 Impact factor: 20.096
Authors: A L Potosky; K Knopf; L X Clegg; P C Albertsen; J L Stanford; A S Hamilton; F D Gilliland; J W Eley; R A Stephenson; R M Hoffman Journal: J Clin Oncol Date: 2001-09-01 Impact factor: 44.544
Authors: Daniel E Soto; Michael N Passarelli; Stephanie Daignault; Howard M Sandler Journal: Int J Radiat Oncol Biol Phys Date: 2011-05-05 Impact factor: 7.038
Authors: Judd W Moul; Hongyu Wu; Leon Sun; David G McLeod; Christopher Amling; Timothy Donahue; Leo Kusuda; Wade Sexton; Keith O'Reilly; Javier Hernandez; Andrew Chung; Douglas Soderdahl Journal: J Urol Date: 2004-03 Impact factor: 7.450
Authors: Piyush K Agarwal; Natalia Sadetsky; Badrinath R Konety; Martin I Resnick; Peter R Carroll Journal: Cancer Date: 2008-01-15 Impact factor: 6.860
Authors: Brandon A Mahal; Ming-Hui Chen; Andrew A Renshaw; Marian J Loffredo; Philip W Kantoff; Anthony V D'Amico Journal: J Natl Compr Canc Netw Date: 2018-06 Impact factor: 11.908
Authors: Peter S Kirk; Tudor Borza; Megan E V Caram; Dean A Shumway; Danil V Makarov; Jennifer A Burns; Jeremy B Shelton; John T Leppert; Christina Chapman; Michael Chang; Brent K Hollenbeck; Ted A Skolarus Journal: BJU Int Date: 2018-11-12 Impact factor: 5.588
Authors: Jingyi Gong; David Payne; Jesse Caron; Camden P Bay; Bradley A McGregor; Jon Hainer; Ann H Partridge; Tomas G Neilan; Marcelo Di Carli; Anju Nohria; John D Groarke Journal: JACC CardioOncol Date: 2020-11-17
Authors: Jae Won Park; Won Sik Jang; Dong Hoon Koh; Won Sik Ham; Koon Ho Rha; Sung Joon Hong; Young Deuk Choi Journal: Yonsei Med J Date: 2018-07 Impact factor: 2.759